A Schedule 13G was filed on November 9, 2026, by Frazier Life Sciences X, L.P. and related reporting persons, disclosing beneficial ownership of 1,674,321 shares of common stock in Aspen Neuroscience, Inc. following the company's initial public offering.

Key Highlights

  • Shares held: Frazier Life Sciences X, L.P. directly holds 1,674,321 shares of Aspen Neuroscience common stock, par value $0.0001 per share.
  • Ownership percentage: The 1,674,321 shares represent 5.8% of the class, calculated based on 29,102,905 shares anticipated to be outstanding following the issuer's initial public offering.
  • Triggering event: The date of event requiring this filing is listed as November 2, 2026, coinciding with the period after the issuer's IPO, as referenced in the final prospectus filed with the SEC on October 30, 2026.
  • Voting and dispositive power: All 1,674,321 shares carry shared voting power and shared dispositive power among the reporting persons; no reporting person holds sole voting or sole dispositive power.
  • Reporting persons: The five reporting persons are Frazier Life Sciences X, L.P., FHMLS X, L.P., FHMLS X, L.L.C., James N. Topper, and Patrick J. Heron, all based in Palo Alto, California.
  • Control structure: According to the filing, FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P., FHMLS X, L.L.C. is the general partner of FHMLS X, L.P., and Heron and Topper are the members of FHMLS X, L.L.C.

Frazier Life Sciences Group Structure and Ownership in Aspen Neuroscience After IPO

The Schedule 13G, filed November 9, 2026, covers common stock of Aspen Neuroscience, Inc. (CUSIP 044933109), a company headquartered at 10835 Road to the Cure, Suite 100, San Diego, CA, 92121. According to the filing, the event requiring the statement occurred on November 2, 2026. The percentage of class listed for each reporting person, 5.8%, is calculated based on 29,102,905 shares of common stock "anticipated to be outstanding following the Issuer's initial public offering, as set forth in the Issuer's final prospectus filed with the Securities and Exchange Commission (the 'SEC') on October 30, 2026," the filing states.

The filing identifies five reporting persons: Frazier Life Sciences X, L.P. (FLS X), FHMLS X, L.P., FHMLS X, L.L.C., James N. Topper, and Patrick J. Heron. All five share a principal business address of c/o Frazier Life Sciences Management, L.P., 1001 Page Mill Rd, Building 4, Suite 200B, Palo Alto, CA 94304. The entities are organized in Delaware, while Topper and Heron are identified as United States citizens. The filing discloses that FLS X directly holds the 1,674,321 shares, and that the shared voting and dispositive power attributed to FHMLS X, L.P., FHMLS X, L.L.C., Topper, and Heron each derive from shares held directly by FLS X.

The filing notes: "Except as specifically stated herein, the filing of this Statement shall not be construed as an admission that any Reporting Person or any of the foregoing is, for the purposes of Section 13(d) and/or Section 13(g) of the Act or otherwise, the beneficial owner of any securities covered by this Schedule 13G or a member of a 'group' with any other person."

What Was Disclosed

A Schedule 13G filed November 9, 2026 reports that five affiliated Frazier Life Sciences entities and individuals collectively hold 1,674,321 shares of Aspen Neuroscience, Inc. common stock, representing 5.8% of the class as of the company's IPO, with all voting and dispositive power held on a shared basis.